 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || izuforant (JW1601) / JW Pharma
Clinical, P1 data, PK/PD data, Journal: Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study. (Pubmed Central) - Oct 21, 2024
ESC inhibition was observed even at doses as low as 10?mg; however, this inhibition became stronger and lasted longer as the dose increased. All izuforant doses were well tolerated, and no discontinuations due to adverse events (AE) or deaths were reported.
- izuforant (JWP1601) / LEO Pharma
Phase classification: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Mar 21, 2024
P2, N=20, Completed, Sponsor: LEO Pharma
All izuforant doses were well tolerated, and no discontinuations due to adverse events (AE) or deaths were reported. Phase classification: P2a --> P2
- || JWP1601 / LEO Pharma
P2a data, Journal: Targeting Histamine Receptor 4 in Cholinergic Urticaria with Izuforant (LEO 152020): Results from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Crossover trial. (Pubmed Central) - Feb 3, 2024
P2a
This was the first study to explore the role of H4R as a therapeutic target in urticaria. Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements in the primary endpoint and all but one prespecified exploratory endpoint in CholU vs placebo.
- |||| izuforant (JWP1601) / JW Pharma
Trial completion: Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 14, 2023
P2, N=216, Completed, Sponsor: LEO Pharma
Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements in the primary endpoint and all but one prespecified exploratory endpoint in CholU vs placebo. Active, not recruiting --> Completed
- ||| izuforant (JWP1601) / JW Pharma
Enrollment closed: Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - May 6, 2023
P2, N=224, Active, not recruiting, Sponsor: LEO Pharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || izuforant (JWP1601) / JW Pharma
Trial completion date, Trial primary completion date: Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 2, 2023
P2, N=224, Recruiting, Sponsor: LEO Pharma
Recruiting --> Active, not recruiting Trial completion date: Jan 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- || izuforant (JWP1601) / LEO Pharma
Trial completion: A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People (clinicaltrials.gov) - Jan 6, 2023
P1, N=28, Completed, Sponsor: LEO Pharma
Trial completion date: Jan 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Aug 2023 Recruiting --> Completed
- || izuforant (JWP1601) / LEO Pharma
Enrollment open: A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People (clinicaltrials.gov) - Sep 21, 2022
P1, N=28, Recruiting, Sponsor: LEO Pharma
Recruiting --> Completed Not yet recruiting --> Recruiting
- || izuforant (JWP1601) / LEO Pharma
Trial completion: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Sep 2, 2022
P2a, N=20, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- || izuforant (JWP1601) / LEO Pharma
New P1 trial: A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People (clinicaltrials.gov) - Aug 19, 2022
P1, N=28, Not yet recruiting, Sponsor: LEO Pharma
- | izuforant (JWP1601) / LEO Pharma
Trial completion date, Trial primary completion date: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Mar 22, 2022
P2a, N=28, Recruiting, Sponsor: LEO Pharma
Recruiting --> Completed Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022
- |||| izuforant (JWP1601) / JW Pharma
Enrollment open: Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2021
P2, N=224, Recruiting, Sponsor: LEO Pharma
Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2022 --> Aug 2022 Not yet recruiting --> Recruiting
- | izuforant (JWP1601) / LEO Pharma
Trial completion date, Trial primary completion date: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Dec 2, 2021
P2a, N=28, Recruiting, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- ||||| izuforant (JWP1601) / JW Pharma
New P2 trial: Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 10, 2021
P2, N=224, Not yet recruiting, Sponsor: LEO Pharma
- || izuforant (JWP1601) / LEO Pharma
Enrollment open: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Jun 11, 2021
P2a, N=28, Recruiting, Sponsor: LEO Pharma
Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- || izuforant (JWP1601) / LEO Pharma
New P2a trial: Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria (clinicaltrials.gov) - Apr 22, 2021
P2a, N=28, Not yet recruiting, Sponsor: LEO Pharma
- || izuforant (JWP1601) / LEO Pharma
Trial completion: A Trial to Evaluate the Effect of Food on LEO 152020 (clinicaltrials.gov) - Dec 19, 2020
P1, N=12, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- || izuforant (JWP1601) / LEO Pharma
Enrollment open: A Trial to Evaluate the Effect of Food on LEO 152020 (clinicaltrials.gov) - Nov 30, 2020
P1, N=12, Recruiting, Sponsor: LEO Pharma
Recruiting --> Completed Not yet recruiting --> Recruiting
- || izuforant (JWP1601) / LEO Pharma
Enrollment change, Trial initiation date: A Trial to Evaluate the Effect of Food on LEO 152020 (clinicaltrials.gov) - Oct 5, 2020
P1, N=12, Not yet recruiting, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting N=46 --> 12 | Initiation date: Jun 2020 --> Oct 2020
- || izuforant (JWP1601) / LEO Pharma
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: A Trial to Evaluate the Effect of Food on LEO 152020 (clinicaltrials.gov) - May 27, 2020
P1, N=46, Not yet recruiting, Sponsor: LEO Pharma
N=46 --> 12 | Initiation date: Jun 2020 --> Oct 2020 N=12 --> 46 | Trial completion date: Nov 2020 --> Feb 2021 | Initiation date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- ||| izuforant (JWP1601) / LEO Pharma
Trial completion: Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2020
P1, N=102, Completed, Sponsor: JW Pharmaceutical
N=12 --> 46 | Trial completion date: Nov 2020 --> Feb 2021 | Initiation date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jun 2020 --> Dec 2020 Recruiting --> Completed
- || izuforant (JWP1601) / LEO Pharma
New P1 trial: A Trial to Evaluate the Effect of Food on LEO 152020 (clinicaltrials.gov) - Dec 17, 2019
P1, N=12, Not yet recruiting, Sponsor: LEO Pharma
- | izuforant (JWP1601) / LEO Pharma
New P1 trial: Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers (clinicaltrials.gov) - Jul 11, 2019
P1, N=96, Recruiting, Sponsor: JW Pharmaceutical